What will Norway’s infliximab switching study tell us about the safety of switching patients from one biologic medicine to a biosimilar?
From the Blog
Regulators Stand Up for Biosimilars
October 31, 2019
Biosimilar Briefings Review Nature and Impact of Biosimilars on Access
October 1, 2019